Table 2. Neutralization of HIV pseudotype infectivity.

					% neutralization of§
mAb	E2 epitope	Half-maximal binding, μg/ml*	Inhibition of E2-CD81†	Reactivity with 293-T expressed HCV E1E2‡	HIV-H E1E2	HIV SF162
7/59	384-391	0.01	-	NT	<5	<5
6/82a	384-395	2.0	-	NT	<5	<5
6/16	384-395	0.02	-	+/+	<5	<5
9/27	396-407	0.04	-	+/+	≥99	<5
9/86a	cHVR¶	1.0	-	NT	<5	<5
3/11	412-423	0.02	+	NT	70	<5
2/69a	432-443	NS	+	+/+	≥99	<5
1/39	432-443	0.15	+	NT	20	<5
7/16b	436-447	0.10	+	+/+	≥99	<5
11/20	436-447	0.02	+	NT	≥99	<5
6/1a	464-471	1.20	-	NT	<5	<5
6/41a	480-493	NS	+	NT	<5	<5
2/64a	524-531	0.08	+	NT	40	<5
9/75	524-531	0.01	+	+/+	<5	<5
6/53	544-551	0.80	-	+/+	<5	<5
B4a1	HIV gp120	NA	NA	NA	<5	≥99

NA, not applicable; NT, not tested

^*mAb recognition of truncated soluble E2, relative affinities are shown as the concentration (μg/ml) required to give half-maximal binding in a capture ELISA (8)

^†mAb (10 μg/ml) inhibition of soluble E2 binding to GST-humCD81 (8)

^‡mAb (10 μg/ml) reactivity with nonpermeabilized and permeabilized 293-T cells transfected with NL4.3.Luc.R^-E^- and pE1E2 (depicted in Fig. 1) (represented as +/+ non-perm/perm cell recognition)

^§mAb (10 μg/ml) neutralization of HIV-H E1E2 and HIV SF 162 (1 ng per well inoculum) infection of Huh-7.5 and Hos.CD4.R5 cells, respectively, as determined by inhibition of luciferase activity

^¶cHVR, conformation-dependent epitope within the HVR